Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2000-05-26
2001-10-23
Jones, Dwayne C. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S518000
Reexamination Certificate
active
06306858
ABSTRACT:
FIELD OF THE INVENTION
This invention relates to pharmacologically-active, anti-inflammatory compounds, and more specifically to long aliphatic chain esters of selected zwitterionic organic compounds derived from naturally occurring taurine. This invention pertains to novel zwitterionic compounds with pharmacologic activity including, but not limited to, the use as an antiinflammatory.
BACKGROUND OF THE INVENTION
Any inflammation that occurs in the mammalian body is the clinical result of a sequence of events known as the arachidonic acid (ARA) cascade. Cell membranes consist of phospholipids. including fatty acids, one of which is ARA. In the inflammation process, the first step is the release of ARA from the phospholipid. The next step is the conversion of ARA into the specific mediator of inflammation. One pathway is the cyclooxygenase and the other is called the lipoxygenase pathway. Cortisone, along with other selected steroidal agents. block both inflammation pathways by inhibiting ARA release.
The mode of action of HEPES-ester is thought to be at the level of leukotrienes B4, but it is also possible that it occurs at higher levels in the inflammatory cascade, perhaps at the phospholipase A2 (PPLA2). Inhibition of PPLA2 action would arrest the aforedescribed cascade effect from being initiated.
Medical science looks for other biochemicals that lack the recognized side effects of prolonged steroid-based (cortisone) medications. One known human biochemical, taurine, synthesis of which occurs in the mammalian liver, and has demonstrated anti-inflammatory activity when administered centrally, but not when administered subcutaneously or interperitoneally. N-substituted derivatives of taurine include: 4-(2-Hydroxyethyl)-1-piperazine ethenesulfonic acid; C
8
H
18
N
2
O
4
S, which is commonly identified in the technical literature as H
EPES
(Merck Index, 12th edition monograph #4687). H
EPES
is available commercially from Angus Chemicals, as the sodium salt or, as the free acid. The scientific literature reports that intravenous injection of (14-C) H
EPES
, or of (3H) taurine, demonstrated rapid clearance, but with a significantly longer half-life compared with taurine. Mahon et al theorized that the greater anti-inflammatory effects of H
EPES
(sodium salt and the acid) compared with taurine, may be due to its slower systemic distribution or clearance, in vivo. The art suggest that H
EPES
is a significant agent to reduce cellular inflammation and cellular proliferation. However, the delivery systems for the H
EPES
treatment of inflammation remain to be optimized.
It is thus a principal object of this invention to provide a H
EPES
-based compound, an ester, and a pharmaceutical formulation including the ester, that is adapted for use in topically applied products to reduce symptoms of skin inflammation, wherein the particular etiology of the inflammation does not call for, or require, the use of antibiotics or germicidal compositions. The improved formulations for epidermal penetration, on bruises, muscle strains and sprains are also areas of useful treatment.
It is another object of the invention to combine the H
EPES
molecule with selected aliphatic acids, as the active ingredient of topical applications, which permit the H
EPES
moiety to penetrate the skin and so to better effect its anti-inflammatory nature.
It is a further object of the invention to provide a H
EPES
-containing active ingredient that is not limited to the known subcutaneous injection or IV infusion routes, but may also effective as a topical formulation.
A still further object of the invention is to provide H
EPES
esters as a cosmetic formulation ingredient, as a co-emulsifier, usable with topical analgesics.
Still another object of the invention is in a cosmetic preparation to incorporate an anti-skin ageing active ingredient.
These and other objects and benefits of this invention will become apparent from a study of the following specification.
SUMMARY OF THE INVENTION
The present invention relates to a composition and method for the treatment of inflammatory conditions in mammals, by the topical administration of selected Zwitterionic ester compositions, serving as safe and effective substances. Among useful Zwitterionic compounds which are preferred include PIPES, BES, POPSO, and preferably HEPES, when esterified, then alone, or in combination with other therapeutic ingredients (see PCT patent document). They are employed by applying to an affected area of the skin, a therapeutically effective amount of at least one skin compatible, Zwitterionic-Ester having the generic formula:
wherein M is an alkali metal and R is a naturally occurring, straight-chain, saturated or unsaturated, aliphatic acid, the esters of which form fatty acids in nature.
Preferably, Zwitterionic-ester has at least one pKa value at 20° C. in the range of 6.0-8.3 to permit its use on human skin, i.e., the ester exists mainly in its dipolar form, in the pH range of 6.0-8.3.
The isoelectric (ISO) point is the pH at which the net charge on a molecule in solution is 0. At this pH, amino acids exist almost entirely in the Zwitterionic state, i.e., the positive and negative groups are equally ionized. A solution of amino acids at the ISO point exhibits minimum conductivity, osmotic pressures, and viscosity.
Such dipolar molecules contain, for example, hydroxy groups and amino groups, and also acid groups, like phosphoric, carboxylic or sulfonics acid groups and, generally have pKa's in the range of 6.15-8.4.
Preferred aliphatic values for the ester moiety of HEPES ester are n-butanoic; isobutyric, n-valeric, palmitic, and stearic, behenyl, lauric, mynistic, (and their isomers) among the saturated aliphatics; and oleic and linoleic, among the unsaturated aliphatics.
The invention also provides a pharmaceutical composition for application to human skin in the treatment of inflammation comprising at least one of the above Zwitteronic-esters as the active ingredient, together with a pharmacologically acceptable topical carrier or base.
These esters may be used in the treatment of arthritis, myositis, insect bites, sunburn, psoriasis, atopic dermatitis, and other inflammatory processes of muscle, connective tissue, or skin appendages.
DETAILED DESCRIPTION OF THE INVENTION
The effective proportion of the active ingredient, by weight of the formulation, is in the range of 1 to 20%, preferably 5 to 10%. In the most preferred composition, the effective proportion lies in the range of 6 to 8. Not every compound falling within the general definition given above, is suitable for topical use in the method of the invention. Some few will prove to be contraindicated. Nevertheless, the exclusion of ineffective active ingredients is a matter well within the competence of the skilled pharmacologist in the conduct of the anti-inflammatory evaluation protocols for disclosed HEPES-esters.
The topical base is selected from a wide variety of compositions, formulated according to known principals for pharmaceutical purposes. Such compositions include creams, solids, ointments, lotions, and film-forming solutions among others. They may be presented in boxes, jars, or compressible tubes, both collapsible and non-collapsible. The solids may be presented as sticks for rubbing onto the skin. Some of the topical bases may be presented as papers, woven or non-woven fabric pieces, or pads, all being impregnated with composition.
The invention relates to HEPES derivatives which are pharmacologically active as anti-phospholipase and anti-inflammatory compounds specifically, wherein the active ingredients are certain long chain esters of selected zwitterionic compounds, based on an N-substituted taurine, namely aliphatic esters of H
EPES.
The novel compounds may exist as at least one of the following five groups: ester, ether, urethane, amide, or urea of all of the following known compounds, and their salt forms. Preferred Zwitterionic-esters are prepared from the below listed sulfonic acids.
ACES—N-(2-Acetamido)-2 amino ethane sulfonic acid.
AMPSO—3-&lsq
Pugliese Peter M.
Pugliese Peter T.
Dinsmore & Shohl LLP
Jones Dwayne C.
LandOfFree
Zwitterionic fatty acid compounds for anti-inflammation does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Zwitterionic fatty acid compounds for anti-inflammation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Zwitterionic fatty acid compounds for anti-inflammation will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2617131